Clinical Trial Update: Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma. [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing HLX01 to Mabthera in CD20-positive follicular lymphoma with low tumor burden was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• HLX01 (null)
• MabThera (rituximab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: CD20-positive Follicular Lymphoma, With Low Tumour Burden | Phase 3 | Status: WITHDRAWN